Chris H Takimoto insider trades: IGM Biosciences (IGMS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Chris reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 13, 2024 | IGMS | ↓ Sell | 1,487 | $11.54 | $17K | Direct | Sep 17, 2024 (4d) |
| Jun 14, 2024 | IGMS | ↓ Sell | 1,570 | $7.58 | $12K | Direct | Jun 18, 2024 (4d) |
| Mar 14, 2024 | IGMS | ↓ Sell | 5,424 | $10.01 | $54K | Direct | Mar 15, 2024 (1d) |
| Nov 29, 2023 | IGMS | ↓ Sell | 1,180 | $6.21 | $7K | Direct | Dec 1, 2023 (2d) |
| May 23, 2023 | IGMS | ↓ Sell | 1,259 | $12.31 | $15K | Direct | May 25, 2023 (2d) |
| Mar 14, 2023 | IGMS | ↓ Sell | 1,768 | $18.73 | $33K | Direct | Mar 16, 2023 (2d) |
| Dec 16, 2022 | IGMS | ↓ Sell | 5,430 | $18.98 | $103K | Direct | Dec 20, 2022 (4d) |
| Nov 23, 2022 | IGMS | ↓ Sell | 877 | $21.57 | $19K | Direct | Nov 28, 2022 (5d) |
| May 24, 2022 | IGMS | ↓ Sell | 938 | $17.10 | $16K | Direct | May 26, 2022 (2d) |
| Apr 1, 2020 | FTSV | ↓ Sell | 79,195 | $95.42 | $7.6M | Direct | Apr 3, 2020 (2d) |
| Dec 10, 2019 | FTSV | ↓ Sell | 10,000 | $35.00 | $350K | Direct | Dec 11, 2019 (1d) |
| Dec 9, 2019 | FTSV | ↓ Sell | 10,000 | $30.00 | $300K | Direct | Dec 10, 2019 (1d) |
| Aug 16, 2019 | FTSV | ↓ Sell | 663 | $6.36 | $4K | Direct | Aug 21, 2019 (5d) |
| May 3, 2019 | FTSV | ↓ Sell | 8,000 | $17.99 | $144K | Direct | May 7, 2019 (4d) |
| Apr 4, 2019 | FTSV | ↓ Sell | 8,000 | $16.39 | $131K | Direct | Apr 8, 2019 (4d) |
| Mar 4, 2019 | FTSV | ↓ Sell | 8,000 | $16.94 | $136K | Direct | Mar 6, 2019 (2d) |
| Feb 19, 2019 | FTSV | ↓ Sell | 2,500 | $15.05 | $38K | Direct | Feb 21, 2019 (2d) |
| Feb 4, 2019 | FTSV | ↓ Sell | 8,000 | $14.86 | $119K | Direct | Feb 5, 2019 (1d) |
| Jan 4, 2019 | FTSV | ↓ Sell | 8,000 | $15.55 | $124K | Direct | Jan 8, 2019 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Chris H Takimoto's insider trades
Chris H Takimoto is Chief Medical Officer at IGM Biosciences (IGMS). Since Jan 4, 2019, Chris has reported no open-market purchases and 19 sales worth $9.2M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (13 filings), option exercises (8 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IGMS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.